A phase II trial of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor

被引：0
|
作者：
Wang, X. [1 ]
Huang, J. [1 ]
Wenyan, C. [2 ]
Sun, Z. [3 ]
Wei, S. [2 ]
Wang, L. [3 ]
机构：
[1] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
[2] Nanchang Peoples Hosp, Dept Breast Med Oncol, Nanchang, Jiangxi, Peoples R China
[3] Jiangxi Canc Hosp, Dept Breast Surg, Nanchang, Jiangxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
452P
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [21] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
    Heo, Mi Hwa
    Kim, Hee Kyung
    Lee, Hansang
    Kim, Ji-Yeon
    Ahn, Jin-Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (05): : 1100 - +
  • [22] Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer
    Carlson, R. W.
    O'Neill, A.
    Vidaurre, T.
    Gomez, H. L.
    Badve, S.
    Sledge, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] A Phase II Study of 9-Nitro-Camptothecin in Patients with Previously Treated Metastatic Breast Cancer
    Kathy D. Miller
    Sharon E. Soule
    LaTrice G. Haney
    Patricia Guiney
    Darryl J. Murry
    Luigi Lenaz
    Show-Li Sun
    George W. Sledge
    Investigational New Drugs, 2004, 22 : 69 - 73
  • [24] A Phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer
    Miller, KD
    Soule, SE
    Haney, LG
    Guiney, P
    Murry, DJ
    Lenaz, L
    Sun, SL
    Sledge, GW
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (01) : 69 - 73
  • [25] Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer
    Ge, Xuan
    Yost, Susan E.
    Lee, Jin Sun
    Frankel, Paul H.
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Chung, Samuel
    Yeon, Christina
    Stewart, Daphne
    Li, Daneng
    Rajurkar, Swapnil
    Somlo, George
    Mortimer, Joanne
    Waisman, James
    Yuan, Yuan
    CANCERS, 2022, 14 (17)
  • [26] Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial
    Tang, P.
    Cohen, S. J.
    Bjarnason, G. A.
    Kollmannsberger, C.
    Virik, K.
    MacKenzie, M. J.
    Brown, J.
    Wang, L.
    Chen, A. P.
    Moore, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] A phase II trial of saracatinib (AZD0530), and oral Src inhibitor, in previously treated metastatic pancreatic cancer
    Messersmith, W. A.
    Nallapareddy, S.
    Arcaroli, J.
    Tan, A.
    Foster, N. R.
    Wright, J. J.
    Picus, J.
    Goh, B. C.
    Hidalgo, M.
    Erlichman, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
    Al-Batran, S. -E.
    Bischoff, J.
    von Minckwitz, G.
    Atmaca, A.
    Kleeberg, U.
    Meuthen, I.
    Morack, G.
    Lerbs, W.
    Hecker, D.
    Sehouli, J.
    Knuth, A.
    Jager, E.
    BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1615 - 1620
  • [29] The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
    S-E Al-Batran
    J Bischoff
    G von Minckwitz
    A Atmaca
    U Kleeberg
    I Meuthen
    G Morack
    W Lerbs
    D Hecker
    J Sehouli
    A Knuth
    E Jager
    British Journal of Cancer, 2006, 94 : 1615 - 1620
  • [30] A phase II trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer
    Hahn, O. M.
    Ma, C. X.
    Lin, L.
    Hou, D.
    Sattar, H.
    Olopade, F. O.
    Nanda, R.
    Hoffman, P. C.
    Naughton, M. J.
    Pluard, T.
    Watson, M. A.
    Ellis, M.
    Conzen, S. D.
    Fleming, G. F.
    CANCER RESEARCH, 2009, 69 (02) : 93S - 94S
12345